Follistatin 344
A myostatin-linked muscle-growth name that remains popular in research-market and performance discussions despite limited conventional therapeutic development.
Also referenced as: FS344, Follistatin
Also appears in: Other
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the latest vendor-default policy recorded for that UTC day. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when Follistatin 344 crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Performance. Also surfaces under Other for browsing and discovery.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
FS344, Follistatin
No FDA label signal · 83 trials · 2983 PubMed results
Follistatin 344 has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
Follistatin 344 has 10 name-matched clinical trials (highest phase: Phase 4) and 2983 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-02 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What follistatin 344 is
Follistatin 344, often shortened to FS344, is a muscle-growth-associated research-market name tied to myostatin and activin inhibition.
Why it matters
It has stayed popular for years in performance and muscle-enhancement discussions even though the formal therapeutic-development story is much thinner and more complicated than the market hype suggests.
Regulatory context
Follistatin 344 is not FDA approved as a mainstream peptide therapy. The name is most relevant in research-market, performance, and anti-doping conversations.
Practical reading note
This is one of the clearest examples of a compound that is culturally important in peptide circles even when the clean clinical-development pathway is limited.